Morgan Stanley favors the globalization and structural recovery opportunities in China's healthcare sector

Overview

This is a Morgan Stanley investor presentation on China's healthcare sector, covering pharmaceuticals, biotechnology, cro/cdmo, medical devices, internet healthcare, healthcare services, traditional Chinese medicine, retail pharmacies, pharmaceutical distribution, and APIs. The central thesis is that China's healthcare sector is becoming increasingly differentiated amid domestic demand, policy, and cost pressures, with innovative drug globalization, recovery in clinical outsourcing, medical device globalization, and improving hospital capital expenditure representing the main structural opportunities.

Core views

Key views include: first, China's innovative drugs are entering the Globalization 2.0 phase, with the global pharmaceutical patent cliff creating demand-side pull and Chinese companies building supply-side advantages in pipelines, talent, costs, and clinical efficiency; second, transaction structures are expanding from traditional out-licensing to NewCos, co-development, co-commercialization, and strategic alliances, with true value dependent on retained economic interests rather than headline deal value; third, cro/cdmo benefits from rising global outsourcing rates, increasing clinical trial initiations in China, and cost efficiency advantages; fourth, medical devices are supported by improving hospital capital expenditure, localization, and global commercial momentum; fifth, retail pharmacies, traditional Chinese medicine, and pharmaceutical distribution continue to face consumption, regulatory, reimbursement, and pricing pressure, although leading-player consolidation and cost optimization provide room for recovery.

Analysis framework

The report uses an industry-mapping approach, combining market size, policy events, academic conference catalysts, transaction cases, clinical trial and outsourcing data, hospital surveys, trade data, and ratings tables for covered companies to assess growth drivers, policy constraints, and investment implications across China's healthcare subsectors.

Methodology notes

• Industry Catalyst Trackingpolicy and event tracker

  Globalization push-pull factors

  Tracks NRDL negotiations, DRG/DIP expansion, equipment upgrades, volume-based procurement, academic conferences, and drug-list updates to assess short-term catalysts and sector impacts.

• Globalization Analysispush-pull framework

  Globalization push-pull factors

  Uses the gap created by global pharmaceutical patent expirations to explain demand-side pull, and China's biotechnology financing resilience, R&D talent, clinical costs, and regulatory coordination to explain supply-side momentum.

• Transaction Value Assessmentretained economics assessment

  Retained economic interest assessment

  The report notes that the headline value of licensing, co-development, and NewCo transactions may overstate their validation significance; attention should be paid to upfront payments, milestones, royalties, equity, and co-commercialization rights as the true economic interests.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• China innovative drugs/biotechnology

  Core beneficiary asset

  Strengths

  The global pharmaceutical patent cliff creates external demand, while Chinese companies are improving their pipelines, talent base, clinical cost structure, and business development capabilities.

  Weaknesses

  Global clinical design, patient composition, and regulatory acceptance will continue to determine whether assets can truly be translated into value.

  Comparison

  Compared with traditional domestic-demand pharmaceutical companies, innovative drug companies rely more heavily on global licensing, NewCos, and strategic partnerships to realize value.

  Risks

  Transaction economic interests being overstated by headline value, overseas regulatory uncertainty, clinical failures, and financing-cycle volatility.

• cro/cdmo

  Benefiting from R&D outsourcing and the establishment of R&D bases in China

  Strengths

  Cost, efficiency, technical capabilities, and the regulatory environment support cooperation between MNCs/biopharma companies and Chinese cro providers.

  Weaknesses

  Recovery in orders and book-to-bill still require validation, and the industry supply-demand normalization process may be uneven.

  Comparison

  Compared with individual pharmaceutical companies, cro/cdmo companies have greater exposure to industry R&D capital expenditure and global outsourcing rates.

  Risks

  Geopolitical policies, customer budget reductions, capacity utilization, and price competition.

• Medical devices

  Driven by hospital capital expenditure and global commercial momentum

  Strengths

  China's TAM is approximately Rmb1.2trn, hospital capital expenditure expectations are improving, and some companies are raising their overseas revenue targets.

  Weaknesses

  The domestic market remains affected by reimbursement, tenders, and regional VBP.

  Comparison

  Compared with pharmaceuticals, medical devices are more influenced by hospital finances, equipment upgrades, and capital expenditure cycles.

  Risks

  Expansion of VBP, hospital cash flow pressure, export competition, and product iteration risks.

• Retail pharmacies

  Consolidation and efficiency improvement theme

  Strengths

  Leading players are expanding through acquisitions, franchising, and self-operated stores, while AI and optimization of underperforming stores can support profit recovery.

  Weaknesses

  Weak same-store sales, regulatory inspections, price reductions, and soft consumption continue to weigh on revenue.

  Comparison

  Leading chains have greater consolidation capabilities and compliance advantages than small and mid-sized pharmacies.

  Risks

  Reform of medical insurance individual accounts, tighter regulation, higher-than-expected store closures, and insufficient recovery in customer traffic.

• Traditional Chinese medicine

  Stable cash flow and dividends, but growth under pressure

  Strengths

  Some companies have stable cash flow and relatively high dividend yields, while declining natural musk prices help reduce costs.

  Weaknesses

  Consumer demand, input costs, reimbursement cost controls, and tender price reductions continue to pressure profitability.

  Comparison

  Compared with innovative drugs, traditional Chinese medicine has greater defensive and cash-flow characteristics.

  Risks

  Weak demand, policy-driven cost controls, raw material price volatility, and aging brands.

• APIs

  Asset linked to export and pricing cycles

  Strengths

  Chinese API companies have high export shares, and some product categories occupy important positions in global supply chains.

  Weaknesses

  Pricing is significantly affected by supply and demand, input costs, and global trade.

  Comparison

  Compared with innovative drugs and medical devices, APIs are more cyclical and cost-driven.

  Risks

  Price declines, trade restrictions, excess capacity, and foreign exchange volatility.

Key data

• China pharmaceutical market sizeApproximately Rmb1.8trnThe report states that China's pharmaceutical market accounts for approximately 15% of the global pharmaceutical market.
• Global pharmaceutical company cro outsourcing rateReaching 62% by 2030eUsed to support the medium-term upside view for cro/cdmo demand.
• China medical device market sizeApproximately Rmb1.2trnUsed by the report to measure the domestic medical device TAM.
• Expected hospital capital expenditure4.7% weighted-average growth in 2026Based on an AlphaWise survey of approximately 80 Chinese hospital managers.
• Retail pharmacy store changesApproximately 22,000 net closures in 2025, with approximately 680,000 stores at year-endIndustry consolidation remains underway, with leading players expanding through acquisitions, franchising, and self-operated stores.
• Price of natural musk in traditional Chinese medicineDeclining from RMB1.65mn/kg to Rmb520k/kgFrom early 2025 to June 2026, an imported natural musk pilot program drove prices lower.
• China medical device trade2025 imports of USD48.0bn and exports of USD52.4bnThe report table shows a 2025 trade balance of -USD4.4bn.
• China API export revenue share43% in 2024Exports account for a relatively high share of revenue for Chinese API companies.

Impact & implications

In terms of investment implications, the report favors subsectors benefiting from globalization, monetization of innovative assets, recovery in outsourcing demand, improving hospital capital expenditure, and industry consolidation. Relatively cautious areas include traditional Chinese medicine, retail pharmacies, pharmaceutical distribution, and certain API businesses that are more exposed to reimbursement cost controls, volume-based procurement, weak consumption, regulatory inspections, and pricing declines.

Risks

• NRDL negotiations, DRG/DIP expansion, VBP, and medical insurance payment reforms may reduce prices and profit margins.
• Globalization of innovative drugs requires overseas clinical designs, patient populations, and regulatory acceptability, creating translation uncertainty.
• Transaction headline value may overstate true validation; investment value may be limited if retained economic interests are minimal.
• Cro/cdmo order recovery, capacity utilization, and customer budgets are subject to cyclical fluctuations.
• Retail pharmacies and traditional Chinese medicine are affected by weak consumption, regulatory inspections, price reductions, and reform of medical insurance individual accounts.
• Geopolitical developments and overseas regulatory policies may affect Chinese data, clinical filings, exports, and cross-border cooperation.

What to watch

• NRDL and commercial insurance catalog negotiations in 2H26, along with the final drug lists.
• Potential announcements on VBP for biosimilars and progress on local medical device VBP.
• Clinical data from Chinese innovative drugs at conferences including ASCO, ESMO, ASH, and SABCS.
• Upfront payments, retained rights, and subsequent milestones in Chinese innovative drug licensing, NewCo, co-development, and MNC strategic alliance transactions.
• Cro/cdmo book-to-bill, backlog growth, clinical trial initiations, and capacity utilization.
• Hospital capital expenditure, equipment upgrade policies, local fiscal support, and changes in patient demand.
• Retail pharmacy same-store sales, net store closures, franchise expansion, and progress in AI-driven efficiency improvements.